L1 cell adhesion molecule-specific chimeric antigen receptor-redirected Human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Hong, Hao ^a   Brown, Christine E ^a   Ostberg, Julie R ^a   Priceman, Saul J ^a   Chang, Wen Chung ^a   Weng, Lihong ^a   Lin, Paul ^a   Wakabayashi, Mark T ^a   Jensen, Michael C ^b   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; CHIMERIC ANTIGEN RECEPTOR; IMMUNOMODULATING AGENT; L1 CELL ADHESION MOLECULE; L1 CELL ADHESION MOLECULE SPECIFIC CHIMERIC ANTIGEN RECEPTOR; UNCLASSIFIED DRUG; CD45 ANTIGEN; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR; NERVE CELL ADHESION MOLECULE L1;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL EXPANSION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY ASSAY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CANCER TRANSPLANTATION; CELL ADHESION; CONFOCAL MICROSCOPY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LENTIVIRINAE; METABOLISM; NONOBESE DIABETIC MOUSE; OVARY TUMOR; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD45; CELL ADHESION; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; IN SITU HYBRIDIZATION, FLUORESCENCE; LENTIVIRUS; MICE; MICE, INBRED NOD; MICROSCOPY, CONFOCAL; NEOPLASM TRANSPLANTATION; NEURAL CELL ADHESION MOLECULE L1; OVARIAN NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84955499949     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146885     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan; 63(1):11-30. doi: 10.3322/caac.21166 PMID: 23335087
2. Dinh P, Harnett P, Piccart-Gebhart MJ, Awada A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol. 2008 Aug; 67(2):103-12. doi: 10.1016/j.critrevonc.2008.01.012 PMID: 18342536
3. Wefers C, Lambert LJ, Torensma R, Hato SV. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence. Gynecol Oncol. 2015 Feb 26.
4. Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J. 2014 Mar-Apr; 20(2):112-8. PMID: 24667955
5. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014 Apr 24; 123(17):2625-35. doi: 10.1182/blood-2013-11-492231 PMID: 24578504
6. Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. CART cells: driving the road from the laboratory to the clinic. Immunol Rev. 2014 Jan; 257(1):91-106. doi: 10.1111/imr.12126 PMID: 24329792
7. ∗ genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother. 2012 Aug; 61(8):1243-53. doi: 10.1007/s00262-012-1201-0 PMID: 22258792
8. Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer immunology research. 2013 Jul; 1(1):43-53. PMID: 24409448
9. Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR, et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 2010 Jul 15; 16(14):3594-606. doi: 10.1158/1078-0432.CCR-10-0192 PMID: 20628030
10. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. Aphase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):6106-15. PMID: 17062687
11. Daponte A, Kostopoulou E, Kollia P, Papamichali R, Vanakara P, Hadjichristodoulou C, et al. L1 (CAM) (CD171) in ovarian serous neoplasms. Eur J Gynaecol Oncol. 2008; 29(1):26-30. PMID: 18386459
12. Hong H, Stastny M, Brown C, Chang WC, Ostberg JR, Forman SJ, et al. Diverse Solid Tumors Expressing a Restricted Epitope of L1-CAM Can Be Targeted by Chimeric Antigen Receptor Redirected T Lymphocytes. J Immunother. 2014 Feb-Mar; 37(2):93-104. PMID: 24509172
13. Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW, et al. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol. 2007 May; 14(5):1703-11. PMID: 17211730
14. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze'ev A. L1-CAM in cancerous tissues. Expert Opin Biol Ther. 2008 Nov; 8(11):1749-57. doi: 10.1517/14712598.8.11.1749 PMID: 18847309
15. Schroder C, Schumacher U, Fogel M, Feuerhake F, Muller V, Wirtz RM, et al. Expression and prognostic value of L1-CAM in breast cancer. Oncol Rep. 2009 Nov; 22(5):1109-17. PMID: 19787228
16. Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res. 2006 Jan 15; 66(2):936-43. PMID: 16424028
17. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007 Apr; 15(4):825-33. PMID: 17299405
18. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8+T cells in immunodeficientmice. Blood. 2011 Feb 10; 117(6):1888-98. doi: 10.1182/blood-2010-10-310599 PMID: 21123821
19. Gonzalez S, Naranjo A, Serrano LM, Chang WC, Wright CL, Jensen MC. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. Journal of Gene Medicine. 2004; 6(6):704-11. PMID: 15170741
20. Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A, et al. Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy. Mol Ther. 2015 Apr; 23(4):757-68. doi: 10.1038/mt.2014.208 PMID: 25366031
21. Nguyen P, Moisini I, Geiger TL. Identification of a murine CD28dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function. Blood. 2003 Dec 15; 102(13):4320-5. PMID: 12946999
22. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006 Nov 15; 66(22):10995-1004. PMID: 17108138
23. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol. 2004 May; 22(5):589-94. PMID: 15064769
24. Jonnalagadda M, Brown CE, Chang WC, Ostberg JR, Forman SJ, Jensen MC. Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase. Gene Ther. 2013 Jan 10; 20(8):853-60. doi: 10.1038/gt.2012.97 PMID: 23303282
25. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. 2003 Feb 15; 101(4):1637-44. PMID: 12393484
26. Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011 Aug 4; 118(5):1255-63. doi: 10.1182/blood-2011-02-337360 PMID: 21653320
27. Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, et al. Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale. J Immunother. 2012 Nov; 35(9):689-701. PMID: 23090078
28. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004 Dec 15; 64(24):9160-6. PMID: 15604287
29. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, et al. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res. 2008 Feb 15; 68(4):1110-8. doi: 10.1158/0008-5472.CAN-07-2897 PMID: 18281486
30. Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, et al. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-kappaB activation. Ann Oncol. 2012 Jul; 23(7):1795-802. doi: 10.1093/annonc/mdr568 PMID: 22228447
31. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007 Sep 15; 13 (18 Pt 1):5426-35. PMID: 17855649
32. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010 Feb; 18(2):413-20. doi: 10.1038/mt.2009.210 PMID: 19773745
33. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008 Jan 2; 118(1):294-305. PMID: 18060041
34. Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity. 2014 Jul 17; 41(1):116-26. doi: 10.1016/j.immuni.2014.05.018 PMID: 25035956
35. Kakarla S, Gottschalk S. CAR T Cells for Solid Tumors: Armed and Ready to Go? Cancer J. 2014 Mar-Apr; 20(2):151-5. PMID: 24667962
36. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol. 2006 Aug; 37(8):1000-8. PMID: 16867862
37. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 2005 Feb 14; 168(4):633-42. PMID: 15716380
38. Kaifi JT, Zinnkann U, Yekebas EF, Schurr PG, Reichelt U, Wachowiak R, et al. L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. World J Gastroenterol. 2006 Jan 7; 12(1):94-8. PMID: 16440424
39. Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P, Debiec H. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res. 2005 Feb 1; 11(3):1190-7. PMID: 15709188
40. SebensMuerkoster S, Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresis-tance in pancreatic ductal adenocarcinoma cells. Oncogene. 2007 Apr 26; 26(19):2759-68. PMID: 17086212
41. Stoeck A, Gast D, Sanderson MP, Issa Y, Gutwein P, Altevogt P. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol Oncol. 2007 Feb; 104(2):461-9. PMID: 17030349
42. Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP, et al. The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene. 2008 Feb 21; 27(9):1281-9. PMID: 17952127
43. Doberstein K, Wieland A, Lee SB, Blaheta RA, Wedel S, Moch H, et al. L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis. 2011 Mar; 32(3):262-70. doi: 10.1093/carcin/bgq249 PMID: 21097529
44. Li S, Jo YS, Lee JH, Min JK, Lee ES, Park T, et al. L1 cell adhesion molecule is a novel independent poor prognostic factor of extrahepaticcholangiocarcinoma. Clin Cancer Res. 2009 Dec 1; 15(23):7345-51. doi: 10.1158/1078-0432.CCR-09-0959 PMID: 19920102
45. Fischer E, Grunberg J, Cohrs S, Hohn A, Waldner-Knogler K, Jeger S, et al. L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer. Int J Cancer. 2012 Jun 1; 130(11):2715-21. doi: 10.1002/ijc.26321 PMID: 21796623
46. Kunkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, et al. Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD. Cancer immunology research. 2015 Apr; 3(4):368-79. doi: 10.1158/2326-6066.CIR-14-0200 PMID: 25576337
47. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010 Nov 15; 70(22):9053-61. doi: 10.1158/0008-5472.CAN-10-2880 PMID: 20926399
48. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 3; 365(18):1673-83. doi: 10.1056/NEJMoa1106152 PMID: 22047558
49. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101. doi: 10.1038/mt.2013.185 PMID: 23939024
50. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014 Oct 11; 384 (9951):p. doi: 10.1016/S0140-6736(13)62146-7 PMID: 24767708